These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 12853808)

  • 1. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Narayan P; Evans CP; Moon T
    J Urol; 2003 Aug; 170(2 Pt 1):498-502. PubMed ID: 12853808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia.
    Schulman CC; Lock TM; Buzelin JM; Boeminghaus F; Stephenson TP; Talja M;
    J Urol; 2001 Oct; 166(4):1358-63. PubMed ID: 11547074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
    Schulman CC; Cortvriend J; Jonas U; Lock TM; Vaage S; Speakman MJ
    Eur Urol; 1996; 29(2):145-54. PubMed ID: 8647140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group.
    Schulman CC; Cortvriend J; Jonas U; Lock TM; Vaage S; Speakman MJ
    Eur Urol; 1999 Dec; 36(6):609-20. PubMed ID: 10559616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.
    Narayan P; Lepor H
    Urology; 2001 Mar; 57(3):466-70. PubMed ID: 11248621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia).
    Abrams P; Speakman M; Stott M; Arkell D; Pocock R
    Br J Urol; 1997 Oct; 80(4):587-96. PubMed ID: 9352698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
    Chapple CR; Wyndaele JJ; Nordling J; Boeminghaus F; Ypma AF; Abrams P
    Eur Urol; 1996; 29(2):155-67. PubMed ID: 8647141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Our experience with the treatment of benign prostatic hyperplasia (BPH) with tamsulosin.
    Cervenakov I; Fillo J
    Bratisl Lek Listy; 2001; 102(3):138-41. PubMed ID: 11433602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group.
    Lepor H
    Urology; 1998 Jun; 51(6):901-6. PubMed ID: 9609624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
    Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group.
    Narayan P; Tewari A
    J Urol; 1998 Nov; 160(5):1701-6. PubMed ID: 9783935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group.
    Abrams P; Schulman CC; Vaage S
    Br J Urol; 1995 Sep; 76(3):325-36. PubMed ID: 7551841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group.
    Lepor H
    Urology; 1998 Jun; 51(6):892-900. PubMed ID: 9609623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
    Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
    Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report.
    Palacio A; Hernández C; Marqués A; Prats J; Espinosa FJ
    Arch Esp Urol; 2004 May; 57(4):451-60. PubMed ID: 15270291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.